Role of Hb to RDW ratio in metastatic renal cell carcinoma patients treated with first-line immunotherapy combinations.

Authors :: Corianò M
Lazzarin A
Maffezzoli M
Santoni M
Mazzaschi G
Rodella S
Simoni N
Lai E
Maruzzo M
Basso U
Bimbatti D
Iacovelli R
Anghelone A
Fiala O
Rebuzzi SE
Fornarini G
Lolli C
Massari F
Rosellini M
Mollica V
Nasso C
Acunzo A
Silini EM
Quaini F
De Filippo M
Brunelli M
Banna GL
Rescigno P
Signori A
Buti S
Source :: Immunotherapy [Immunotherapy] 2025 Jan; Vol. 17 (1), pp. 25-35. Date of Electronic Publication: 2025 Jan 20.
Publication Year :: 2025
Abstract: Background: The present study aimed to investigate the prognostic and predictive roles of Hb/RDW ratio in patients with mRCC treated with first-line immunotherapy combinations (TKI plus ICI or ICI plus ICI).<br />Materials and Methods: We performed a sub-analysis of a multicenter retrospective observational study (ARON-1 project) involving patients with mRCC treated with first-line immunotherapy combinations.<br />Results: Three hundred and twenty-nine patients were enrolled, 244 males and 85 females. Median age was 65.5 years. The prognostic impact of the Hb/RDW ratio on PFS and OS was observed in the whole population examined. Hb/RDW ratio had a correlation with neutrophil-to-lymphocyte ratio (NLR), a blood inflammatory parameter.<br />Conclusion: Hb/RDW ratio is a new inflammatory prognostic factor, easy to use in daily clinical practice.

Full Text Access

Tools